Therapeutic interventions and adjustments in the management of parkinson disease: Role of combined carbidopa/levodopa/entacapone (stalevo®)

Neuropsychiatric Disease and Treatment

Volumn 6, Issue , 2010, Pages 483-490

  Solla, Paolo ^a   Cannas, Antonino ^a   Marrosu, Francesco ^a   Marrosu, Maria Giovanna ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Carbidopa levodopa entacapone; Parkinson disease

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DIHYDROERGOCRYPTINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR; ENTACAPONE; HOMOCYSTEINE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED RELEASE FORMULATION; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FOLLOW UP; GOLD STANDARD; HEPATITIS; HUMAN; LIVER TOXICITY; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; URINE COLOR; VASCULAR DISEASE;

EID: 79959786768     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s5190     Document Type: Article

References (81)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–39.
2. de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535.
3. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348(14):1356–1364.
4. Müller T. Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety, and patient preference. Patient Preference and Adherence. 2009;3:51–59.
5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson disease. Neurology. 2001;56(11 Suppl 5): S1–S88.
6. Jancovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s Disease. CNS Drugs. 2007; 21(8):677–692.
7. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet. 1977;1(8007):345–349.
8. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson’s disease: strategies for management. CNS Drugs. 2003;17: 475–489.
9. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson Disease. Arch Neurol. 2006;63:1756–1760.
10. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55 Suppl 4:S13–S20; discussion S21–S23.
11. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62 Suppl 1:S17–S30.
12. Olanow CW. Movement disorders: a step in the right direction. Lancet Neurol. 2006;5:3–5.
13. Dewey RB Jr. Management of motor complications in Parkinson’s disease. Neurology. 2004;62 Suppl 4:S3–S7.
14. Riederer P, Gerlach M, Müller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(8):466–479.
15. Jankovic J. Parkinson’s disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000;23: 252–261.
16. Bergamasco B, Frattola L, Muratorio A, Piccoli F, Mailland F, Parnetti L. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand. 2000;101:372–380.
17. Barone P, Bravi D, Bermejo-Pareja F, et al; for Pergolide Monotherapy Study Group. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Neurology. 1999;53:573–579.
18. Shannon KM, Bennett JP Jr, Friedman JH, for Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson‘s disease. Neurology. 1997;49: 724–728.
19. Adler CH, Sethi DK, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology. 1997;49:393–399.
20. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404.
21. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008;4:743–757.
22. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2005;21:343–353.
23. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004; 18:733–746.
24. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284: 1931–1938.
25. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–1053.
26. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–1491.
27. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with levodopa. Neurology. 2002;58 Suppl 3:A82–A83.
28. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–1661.
29. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron. 2010;65(1):135–142.
30. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39–46.
31. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2000;15(5):873–878.
32. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82–85.
33. Henchcliffe C, Schumacher HC, Burgut FT. Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother. 2005;5(6):811–821.
34. Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66: 1200–1206.
35. Olanow CW, Rascol O, Hauser R, et al; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–1278.
36. Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother. 2006;7:1399–1407.
37. Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology. 1993;43:677–681.
38. Koller WC, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1994;44 Suppl 6:S23–S28.
39. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a five year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999; 53(5):1012–1019.
40. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27:135–206.
41. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs. 2000;59(6):1233–1250.
42. Müller T. Tolcapone in the management of Parkinson’s disease. Aging Health. 2006;2(5):709–720.
43. Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol. 1998;245(11 Suppl 3):25–34.
44. Schrag A. Entacapone in the treatment of Parkinson’s disease. Lancet Neurol. 2005;4:366–370.
45. Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psichiatry. 2007;78(9):944–948.
46. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol. 1996;19: 283–296.
47. Heikkinen H, Varhe A, Lyly V, et al. New levodopa. carbidopa and entcapone combination tablets. European J Neurology. 2003;10:164.
48. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62:64–71.
49. ParkinsonStudyGroup. Entacapone improvesmotor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol. 1997;42:747–755.
50. Rinne UK, Larsen JP, Siden A, Worm-Peterson J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:186–189.
51. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol. 2003;10:137–146.
52. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre study. J Neural Transm. 2003;110:239–251.
53. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (catechol-O-methyltransferase) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68:589–594.
54. Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 2001;45:111–118.
55. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm. 2004;111(8):1053–1063.
56. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111:21–28.
57. Poewe W., Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–255.
58. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74:1071–1079.
59. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebocon-trolled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563–1568.
60. Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A; TC-INIT Study Group. Treatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entaca-pone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005; 53(4):197–202.
61. Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006; 114(3):181–186.
62. Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/ benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility – an open-label, 6-week study. J Neural Transm. 2010; 117(3):333–342.
63. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group. Double-blind trial of levodopa/ carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord. 2009;24(4):541–550.
64. Müller T, Muhlack S. Peripheral COMT inhibition prevents levodopa associated homocysteine increase. J Neural Transm. 2009;116(10): 1253–1256.
65. Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neuro. 2005;192:184–193.
66. Hadj TA, Gregoire L, Bangassoro E, Bedard PJ. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol. 2000;23:195–202.
67. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci. 2000;23: S117–S126.
68. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurolog. 2004;62:S47–S55.
69. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234–241.
70. Maratos EC, Jackson MJ, Pearce RK, Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord. 2001;16:631–641.
71. Koller WC, Hutton JT, Tolosa E, Capilldeo R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999; 53:1012–1019.
72. Nissinen H, Kuoppamä M, Leinonen M, Schapira AH. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson_s disease: a long-term, retrospective analysis. Eur J Neurol. 2009;16:1305–1311.
73. Kliveny P, Vecsei L. Novel therapeutic strategies in Parkinson’s disease. Eur J Clin Pharmacol. 2010;66:119–125.
74. Müller T. Role of homocysteine in the treatment of Parkinson’s disease. Expert Rev Neurother. 2008;8(6):957–967.
75. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry. 1995;58(3):293–299.
76. Gorell JM, Johnson CC, Rybicki BA. Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44(10):1865–1868.
77. Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology. 2006;66(12):1941–1943.
78. Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson’s disease patients. Parkinsonism Relat Disord. 2009;15(6): 477–478.
79. de Bonis ML, Tessitore A, Pellecchia MT, et al. Impaired transmethy-lation potential in Parkinson’s disease patients treated with L-dopa. Neurosci Lett. 2010;468(3):287–291.
80. Valkovic P, Benetin J, Blazacek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/ entacapone treated Parkinson patients. Parkinsonism Relat Disord. 2005;11:253–256.
81. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005;11:131–133.